Zhejiang Tailin BioEngineering Co.,Ltd (SHE:300813)
China · Delayed Price · Currency is CNY 20.55
+0.08 (0.39%)
Sep 4, 2026, 3:04 PM CST
SHE:300813 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,491 | 2,948 | 2,093 | 2,665 | 3,863 | 5,197 | |
Market Cap Growth | -35.60% | 40.85% | -21.45% | -31.03% | -25.66% | 103.58% |
Enterprise Value | 2,298 | 2,811 | 2,100 | 2,287 | 3,487 | 4,903 |
Last Close Price | 20.55 | 24.54 | 17.11 | 24.17 | 34.94 | 46.80 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 102.34 | 178.84 | 160.38 | 135.48 | 48.48 | 81.80 |
PS Ratio | 6.94 | 8.68 | 6.00 | 9.88 | 10.33 | 18.35 |
PB Ratio | 3.15 | 3.67 | 2.55 | 4.10 | 5.97 | 10.45 |
P/TBV Ratio | 3.26 | 3.80 | 2.59 | 4.18 | 6.08 | 10.72 |
P/FCF Ratio | 210.80 | 3524.81 | 342.09 | - | 64.13 | 517.06 |
P/OCF Ratio | 37.91 | 61.78 | 84.89 | 1379.38 | 43.22 | 144.51 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 6.40 | 8.28 | 6.02 | 8.48 | 9.33 | 17.31 |
EV/EBITDA Ratio | 74.58 | 126.80 | 73.92 | 163.90 | 47.84 | 76.05 |
EV/EBIT Ratio | 139.81 | 483.24 | 177.78 | 826.90 | 54.67 | 84.80 |
EV/FCF Ratio | 194.50 | 3360.93 | 343.20 | - | 57.88 | 487.78 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | - | - | 0.00 | 0.24 | 0.23 | 0.01 |
Debt / EBITDA Ratio | - | - | 0.13 | 11.29 | 1.89 | 0.11 |
Debt / FCF Ratio | - | - | 0.60 | - | 2.42 | 0.72 |
Net Debt / Equity Ratio | -0.24 | -0.41 | -0.48 | -0.37 | -0.67 | -0.63 |
Net Debt / EBITDA Ratio | -4.95 | -15.00 | -13.95 | -17.15 | -5.92 | -4.89 |
Net Debt / FCF Ratio | -16.30 | -397.65 | -64.75 | 1.37 | -7.17 | -31.37 |
Asset Turnover | 0.39 | 0.35 | 0.36 | 0.28 | 0.47 | 0.47 |
Inventory Turnover | 1.46 | 1.40 | 1.30 | 1.05 | 1.54 | 1.21 |
Quick Ratio | 1.87 | 2.71 | 3.47 | 2.80 | 4.96 | 2.48 |
Current Ratio | 3.61 | 3.61 | 4.66 | 3.95 | 5.90 | 3.35 |
Return on Equity (ROE) | 2.91% | 2.00% | 1.67% | 2.84% | 13.92% | 13.49% |
Return on Assets (ROA) | 1.10% | 0.38% | 0.76% | 0.18% | 5.05% | 6.04% |
Return on Invested Capital (ROIC) | 2.85% | 1.26% | 2.71% | 0.74% | 31.96% | 34.68% |
Return on Capital Employed (ROCE) | 2.10% | 0.70% | 1.40% | 0.30% | 8.00% | 11.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.94% | 0.56% | 0.62% | 0.74% | 2.06% | 1.22% |
FCF Yield | 0.47% | 0.03% | 0.29% | -6.54% | 1.56% | 0.19% |
Dividend Yield | 0.15% | 0.12% | 0.58% | 0.41% | 0.66% | 0.31% |
Payout Ratio | 69.45% | 149.95% | 84.23% | 138.14% | 22.39% | 15.38% |
Buyback Yield / Dilution | -0.56% | -8.27% | 6.00% | -3.09% | -3.28% | -2.57% |
Total Shareholder Return | -0.42% | -8.15% | 6.59% | -2.67% | -2.62% | -2.27% |